Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing a… read more
-
ETF
Equity
- years
198 holdings
$24.21
Price+3.00%
$0.71
$15.543m
Small
$3.209k
Avg Volume$10.385m
$25.81
NAV0.79%
Expense Ratio0.99%
Yield$0.24
Dividend